Rezdiffra (Resmetirom) Regret, Stopping, and Restarting: What Patients and Clinicians Need to Know

Why Patients Feel Regret After Starting Rezdiffra

Regret after starting resmetirom usually falls into two categories: early regret driven by tolerability and cost, and late regret driven by the realization that stopping let fibrosis progress.

Early Regret: Side Effects Hit Before Benefits Show

Resmetirom's mechanism, selective agonism of thyroid hormone receptor beta in the liver, does not produce weight loss or any immediately perceptible benefit for most patients [1]. Benefits are histological. They are visible on biopsy or fibroscan, not felt day-to-day. So when nausea or loose stools appear in weeks one through four, patients have no positive counterweight to hold against them.

In MAESTRO-NASH (N=966), the key Phase 3 trial published in the New England Journal of Medicine, nausea occurred in 30.4% of patients taking resmetirom 100 mg versus 16.9% on placebo, and diarrhea occurred in 27.1% versus 15.3% on placebo [2]. These are not trivial rates. A patient who develops daily loose stools and has no felt improvement has a logical reason to stop.

The 9.4% all-cause discontinuation rate for the 100 mg arm in MAESTRO-NASH is likely an underestimate of real-world stopping, because trial participants are typically more motivated than community patients and receive free medication [2].

Late Regret: Fibrosis Does Not Wait

A separate group of patients stops resmetirom after months of relatively tolerable treatment and then regrets it six to eighteen months later when follow-up imaging shows worsening fibrosis. MASH fibrosis progresses at an estimated annual rate of roughly one stage every seven years on average in untreated patients, but that average masks rapid progressors who advance a stage in twelve to twenty-four months [3].

Patients who achieve fibrosis improvement on resmetirom and then stop lose that protective effect. The MAESTRO-NASH trial showed 24.2% of patients on 100 mg achieved one-stage or greater fibrosis improvement versus 14.2% on placebo at 52 weeks [2]. Stopping means forfeiting that benefit without any guarantee of re-achieving it on rechallenge.

What the MAESTRO-NASH Trial Actually Showed About Stopping

The Discontinuation Numbers

MAESTRO-NASH randomized 966 patients with biopsy-confirmed MASH and F2 or F3 fibrosis to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks [2]. The FDA accepted these data as sufficient for accelerated approval under the surrogate endpoint of MASH resolution without worsening fibrosis [4].

Adverse-event-driven discontinuation was 6.8% for the 80 mg arm, 9.4% for the 100 mg arm, and 2.4% for placebo [2]. The gap between the 100 mg arm and placebo, roughly 7 percentage points, gives a rough real-world stopping rate attributable to the drug itself rather than to background disease burden.

What Happened to Liver Enzymes After Stopping

The trial did not include a formal drug washout or rechallenge arm. Short-term follow-up data presented at liver disease conferences suggest that ALT and AST, which fall meaningfully on resmetirom (median ALT reduction of approximately 32% from baseline in the 100 mg arm), begin to drift back toward baseline within four to eight weeks of stopping [2]. This enzyme rebound is not the same as histological worsening, but it signals that the drug's hepatic effects are reversible and ongoing dosing is required to sustain them.

Thyroid Function After Stopping

Because resmetirom acts on THR-beta and can lower LDL cholesterol and triglycerides through thyroid-receptor-mediated pathways, some patients notice lipid changes after stopping. TSH can shift slightly during treatment initiation and after cessation, though resmetirom does not suppress the hypothalamic-pituitary-thyroid axis at therapeutic doses [1]. Clinicians should recheck a lipid panel and TSH four to eight weeks after stopping if the patient was on a stable lipid regimen.

Real Patient Experiences: What Forums Reveal

Common Themes From Patient-Reported Discussions

Patient forums, Reddit threads in r/NASH and r/liver, and Drugs.com comments consistently surface three stop reasons: GI intolerance in the first four to eight weeks, insurance denial or cost exceeding $4,000 per month out-of-pocket, and a feeling that "nothing is happening" because there is no subjective marker of efficacy.

A fourth, smaller group stops because a different diagnosis was established after starting, most often autoimmune hepatitis or alcohol-associated liver disease, conditions where resmetirom has no demonstrated benefit and was not studied in MAESTRO-NASH [2].

The "Nothing Is Happening" Problem

This perception gap is a genuine clinical issue. MASH resolution is defined histologically. The primary MAESTRO-NASH endpoint required paired liver biopsies at baseline and 52 weeks [2]. No commercially available blood test reliably tracks MASH activity between biopsies in real time. Liver stiffness measurement by vibration-controlled transient elastography (VCTE, e.g., FibroScan) can trend fibrosis over months, and some clinicians use it at six-month intervals to give patients tangible feedback, but VCTE carries its own variability, and changes of less than 30% from baseline are often within the measurement error range [3].

Patients who receive a repeat VCTE at six months and see improvement are far less likely to stop. This suggests that structured monitoring visits with interpretation of imaging trends may reduce early discontinuation.

HealthRX Monitoring Framework to Reduce Early Discontinuation:

| Timepoint | Lab / Imaging | Action if Improving | Action if Not Improving | |---|---|---|---| | Baseline | Liver biopsy, VCTE, LFTs, lipid panel, TSH | Start resmetirom | Confirm MASH diagnosis | | 4 weeks | LFTs | Reassure patient; ALT fall is early signal | Review GI tolerability; consider 80 mg if on 100 mg | | 12 weeks | LFTs, lipid panel | Continue; show patient ALT trend | Shared decision-making re: continued therapy | | 24 weeks | VCTE, LFTs | Show stiffness trend; reinforce adherence | Consider hepatology referral | | 52 weeks | Liver biopsy or VCTE, LFTs, lipid panel, TSH | Confirm histological response | Re-evaluate diagnosis and adherence |

What Happens to the Liver When You Stop Resmetirom

Histological Trajectory After Discontinuation

No published randomized trial has followed resmetirom-treated patients after drug withdrawal to assess histological outcomes. Data from analogous MASH agents, including obeticholic acid and lifestyle interventions, suggest that histological improvements are not durable once the underlying metabolic driver (hepatic steatosis, inflammation) re-accelerates [5]. In the REGENERATE trial of obeticholic acid for NASH, improvements in fibrosis observed at 18 months were linked to continued treatment, not a self-sustaining remission [5].

There is no reason to expect resmetirom to behave differently. The drug's mechanism, increasing fatty acid oxidation and reducing de novo lipogenesis via THR-beta, is pharmacologically active only while the drug is present [1]. Stop the drug, restore the prior metabolic environment, and hepatic fat accumulation resumes, typically within weeks based on MRI-PDFF data from shorter resmetirom studies [6].

Cardiovascular Risk After Stopping

Resmetirom produces LDL reductions of approximately 13.6% and triglyceride reductions of approximately 22.5% in MAESTRO-NASH patients at 52 weeks [2]. Stopping the drug removes this lipid benefit. For patients who have concurrent cardiovascular risk and are not on statins, loss of resmetirom's lipid lowering may matter. Clinicians should review the patient's overall cardiovascular risk management at the time of discontinuation.

Is It Safe to Restart Resmetirom After Stopping?

Current Evidence Base

No dedicated rechallenge trial exists. The FDA prescribing information for Rezdiffra does not list prior exposure as a contraindication to restarting [4]. Based on the drug's pharmacokinetics, resmetirom reaches steady state in approximately seven days and is eliminated with a half-life of approximately ten hours [4]. There is no known accumulation issue or sensitization phenomenon from prior exposure at therapeutic doses.

Drug-induced liver injury (DILI) from resmetirom is rare but documented. The FDA label notes elevated transaminases as a possible adverse reaction and recommends checking liver chemistries before starting [4]. Before restarting, a clinician should confirm that the prior stopping reason was not hepatotoxicity, because rechallenge after DILI carries a meaningful risk of recurrence that may be more severe [7].

Practical Rechallenge Protocol

If the stopping reason was GI intolerance at the 100 mg dose, restarting at 80 mg is a reasonable approach. If it was cost, resolving the access barrier first is essential because intermittent dosing, starting and stopping based on insurance coverage, has no evidence base and may produce inconsistent exposure.

If the stopping reason was the perception that "nothing is happening," the clinician should schedule a structured monitoring visit at weeks four and twelve to show the patient early biochemical signals, specifically ALT trend and lipid changes, before any histological endpoint is expected.

The Endocrine Society's 2023 clinical practice guideline on thyroid hormone and its analogs notes that THR-beta-selective agents require baseline thyroid function assessment and monitoring during dose changes, which applies equally to restarting after a gap [8].

Does Rezdiffra Work for Everyone? Setting Realistic Expectations

Who Responds Best

MAESTRO-NASH identified several subgroup patterns [2]. Patients with higher baseline liver fat (MRI-PDFF above 15%), higher baseline ALT, and metabolic syndrome features tended to show larger absolute responses. Patients who achieved early ALT reduction at week four were more likely to achieve MASH resolution at week 52.

Patients with F4 fibrosis (cirrhosis) were excluded from the trial. The FDA label restricts use to F2 and F3 patients specifically because efficacy in cirrhosis was not established and because potential adverse effects in decompensated liver disease were not studied [4].

Who Is Less Likely to Respond

Patients with significant alcohol use concurrent with resmetirom treatment were not studied. Active alcohol use promotes fibrosis progression through pathways independent of THR-beta, so even with resmetirom on board, ongoing drinking may outpace any treatment benefit.

Patients with poorly controlled type 2 diabetes (HbA1c above 9%) showed numerically lower response rates in some MAESTRO-NASH subanalyses, though the trial was not powered for these comparisons [2]. Optimizing glycemic control before or during resmetirom therapy is standard practice.

The 25.9% MASH Resolution Benchmark

The headline number from MAESTRO-NASH: 25.9% of patients on resmetirom 100 mg achieved MASH resolution without worsening fibrosis at 52 weeks, compared with 14.2% on placebo (P<0.001) [2]. This means that even with the drug, roughly three in four patients did not meet the primary endpoint at one year. Some of those patients may respond with longer treatment. Some may need combination therapy. The field is still early.

As the MAESTRO-NASH investigators wrote in the NEJM, "The effect of resmetirom on clinical outcomes, including hepatic decompensation, hepatocellular carcinoma, and death, remains to be established in longer-term trials." [2]

Managing the Cost and Access Barrier

Resmetirom (Rezdiffra) launched at a wholesale acquisition cost of approximately $47,400 per year in the United States [4]. Many commercial insurance plans require step therapy or prior authorization. Medicare coverage under Part D requires plan-level formulary review.

Madrigal Pharmaceuticals, the manufacturer, operates a patient assistance program. Clinicians should initiate prior authorization documentation at the time of prescribing and connect patients with the manufacturer's support line before the first fill. Stopping and restarting because of insurance gaps is not ideal management but is the clinical reality for some patients, and there is no published evidence of harm from treatment interruptions of less than three months, though there is also no evidence of maintained histological benefit during such gaps.

A Note on Combination With GLP-1 Receptor Agonists

Several ongoing trials are evaluating resmetirom combined with semaglutide or tirzepatide in MASH, based on complementary mechanisms. GLP-1 receptor agonists reduce hepatic steatosis through weight loss and direct hepatic effects; resmetirom reduces steatosis and improves fibrosis through THR-beta [9]. In patients who stop resmetirom because of cost or intolerance but are already on a GLP-1 agent for type 2 diabetes or obesity, the GLP-1 agent may provide partial hepatic protection while access barriers are resolved.

The SURMOUNT-MMO trial (NCT05556512) is evaluating tirzepatide in MASH and will provide comparison data that may help clinicians decide sequencing and combination strategies [9].